HENDRICKS JOHN S

Director HENDRICKS JOHN S sold 8,050,000 shares of CURI at $3.50 on 2025-08-14 for $28,175,000.00, reducing stake by -39.7%.

Director Hendricks sold 8,050,000 shares (8.05M shares), representing -39.7% of his pre-transaction holdings, in a $28,175,000.00 transaction at $3.50, while the stock currently trades at $4.21, down -33.3% over 90 days and -8.9% over 30 days. His prior three sales at CURI (June 10–12, 2025) showed negative 30-day returns averaging -12.1%, a pattern consistent with his broader cross-ticker track record of 3 prior sells averaging -12.1% 30-day returns. The company faces deteriorating fundamentals: annual revenue declined -10.1%, full-year net income was negative, and latest-quarter revenue of $19,012,000.00 ($19.0M) paired with net income of $784,000.00 ($784.0K) indicates marginal profitability. The substantial reduction in Hendricks' stake—from 20,256,188 to 12,206,188 shares—occurs amid a -38.7% pullback from the 52-week high, raising questions about conviction and forward visibility at a company struggling with top-line contraction.

Director John S. Hendricks sold 320,470 shares at blended avg $5.16 in 3 transactions on 2025-06-10/12 ($1.7M); retains 20.45M shares.

Director John S. Hendricks sold 320,470 shares in three separate transactions across three days (June 10–12) at prices ranging from $5.11 to $5.20, netting $1,655,201.80. Despite the sale, he retained 20.45M shares post-transaction, representing a net reduction of only 1.5% of his pre-transaction holdings. The sales occurred with the stock trading at $5.09 current price, within the 52-week range of $0.98–$6.87, and 25.9% below the 52-week high. The company has reported negative full-year net income, though the most recent quarter showed revenue of $15,090,000.00 and net income of $319,000.00, alongside a -10.1% annual revenue growth rate. The multi-day sale pattern and retention of substantial holdings provide limited clear signal regarding overall directional conviction.